Litigation Details for Sanofi-Aventis U.S. LLC v. Cadila Healthcare Limited (D. Del. 2016)

Sanofi-Aventis U.S. LLC v. Cadila Healthcare Limited (D. Del. 2016)

Docket		Date Filed	2016-12-22
Court	District Court, D. Delaware	Date Terminated	2018-01-02
Cause	35:271 Patent Infringement	Assigned To	Gregory Moneta Sleet
Jury Demand	None	Referred To
Patents	6,794,410; 9,186,346
Firms	Shaw Keller LLP
Link to Docket	External link to docket

Details for Sanofi-Aventis U.S. LLC v. Cadila Healthcare Limited (D. Del. 2016)

Date Filed	Document No.	Description	Snippet	Link To Document
2016-12-22				External link to document
2016-12-21	1		infringement of United States Patent Nos. 6,794,410 (“the ‘410 patent,” a true and accurate copy of …United States Patent and Trademark Office granted reexamination certificate C1 6,794,410 for the ‘410 … INFRINGEMENT OF U.S. PATENT NO. 6,794,410 54. Plaintiffs repeat and reallege…INFRINGEMENT OF U.S. PATENT NO. 6,794,410 60. Plaintiffs repeat and reallege…the ‘410 patent. The ‘410 patent will expire on April 15, 2022. 23. The ‘346 patent, titled	External link to document
2016-12-21	4		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 6,794,410 C1; US 9,186,346 …2016 2 January 2018 1:16-cv-01298 830 Patent None District Court, D. Delaware	External link to document

# Sanofi-Aventis U.S. LLC v. Cadila Healthcare Ltd. (1:16-cv-01298): Litigation Summary and Patent Analysis

Last updated: August 27, 2026

Sanofi-Aventis U.S. LLC v. Cadila Healthcare Ltd., No. 1:16-cv-01298, was a Hatch-Waxman patent action in the U.S. District Court for the District of Delaware concerning Cadila’s abbreviated new drug application for generic teriflunomide, the active ingredient in Sanofi’s Aubagio multiple-sclerosis product. The case was resolved without a public merits judgment. Its commercial significance centered on Sanofi’s method-of-use and pharmaceutical patent protection for teriflunomide and the timing of generic entry.

What drug was involved in Sanofi v. Cadila Healthcare?

The litigation involved Aubagio, Sanofi’s oral teriflunomide product for relapsing forms of multiple sclerosis.

Item	Detail
Brand	Aubagio
Active ingredient	Teriflunomide
Dosage form	Oral tablets
Strengths	7 mg and 14 mg
Therapeutic category	Immunomodulator; multiple sclerosis treatment
Regulatory pathway	ANDA under the Hatch-Waxman Act
Plaintiff	Sanofi-Aventis U.S. LLC
Defendant	Cadila Healthcare Ltd.
Court	U.S. District Court for the District of Delaware
Case number	1:16-cv-01298
FDA approval of Aubagio	September 12, 2012
Primary generic risk	Paragraph IV challenge to listed Aubagio patents

The case did not involve a biosimilar application. Teriflunomide is a chemically synthesized small-molecule drug, so Cadila proceeded through the ANDA process rather than the biologics license application pathway under the Public Health Service Act.

What patents protected Aubagio and teriflunomide?

The principal Aubagio patents associated with the litigation were U.S. Patent Nos. 8,404,703 and 9,533,046.

Patent	General subject matter	Relevance to generic entry
U.S. 8,404,703	Teriflunomide treatment methods, including use in multiple sclerosis	Method-of-use protection
U.S. 9,533,046	Additional teriflunomide treatment and dosing claims	Later-expiring method-of-use protection

The 8,404,703 patent was particularly important because its claims addressed administering teriflunomide to treat multiple sclerosis. The 9,533,046 patent extended the patent estate with additional claims covering treatment protocols and related therapeutic use.

Patent expiration dates must be distinguished from FDA regulatory exclusivity. The principal 8,404,703 patent was generally identified with a 2023 expiration period, subject to applicable patent-term adjustments and pediatric exclusivity. The 9,533,046 patent had a later expiration period, generally extending into the late 2020s. Exact Orange Book dates can vary based on patent-term adjustment, terminal disclaimers, and FDA listing data.

When did Aubagio lose exclusivity?

Aubagio’s regulatory exclusivity ended before the principal litigation concluded.

FDA regulatory exclusivity

Aubagio received five-year new chemical entity exclusivity following FDA approval in 2012. That exclusivity period expired in September 2017. Regulatory exclusivity prevented FDA approval of a competing ANDA during the protected period, but it did not prevent Cadila from filing an ANDA or sending a Paragraph IV certification before the regulatory exclusivity expired.

Patent exclusivity

Patent protection extended beyond the NCE exclusivity period. The commercial launch date for a generic therefore depended primarily on the patent settlement, patent validity, infringement findings, and any applicable pediatric extension.

Milestone	Approximate timing
FDA approval of Aubagio	September 12, 2012
NCE exclusivity expiration	September 2017
Sanofi’s Delaware complaint against Cadila	2016
Principal 8,404,703 patent period	Through approximately 2023
Later Aubagio patent protection	Into the late 2020s
Generic teriflunomide approvals	Began after the relevant exclusivity barriers declined

Why did Sanofi sue Cadila under Paragraph IV?

Cadila’s ANDA included a Paragraph IV certification asserting that one or more Orange Book-listed Aubagio patents were invalid, unenforceable, or would not be infringed by Cadila’s proposed generic product.

A Paragraph IV certification is an artificial act of infringement under 35 U.S.C. § 271(e)(2). Sanofi’s complaint activated the Hatch-Waxman litigation framework and generally triggered an automatic 30-month stay of FDA approval, subject to statutory exceptions.

The case therefore had two separate legal functions:

1. It allowed Sanofi to assert patent rights before generic launch.
2. It created a defined litigation window during which Cadila could challenge the listed patents.

The complaint did not itself establish that Cadila’s product would infringe. Sanofi still had to prove infringement under the asserted claims, while Cadila could challenge validity and enforceability.

What was the litigation status of Sanofi v. Cadila Healthcare?

The case did not produce a reported trial judgment or a public Federal Circuit decision determining the validity of the asserted Aubagio patents. The public docket reflects a resolution and dismissal rather than a final merits determination.

The settlement terms were not publicly disclosed in the docket materials. As a result, the record does not establish a publicly stated Cadila launch date, royalty structure, authorized-generic arrangement, or license grant.

Issue	Publicly established position
Merits trial	No reported merits judgment
Patent validity ruling	No reported final ruling in this action
Infringement ruling	No reported final ruling in this action
Settlement	Case resolved without public substantive terms
Cadila launch date	Not publicly established in the case record
License economics	Not publicly disclosed
Authorized generic	Not established by the public docket
Biosimilar proceeding	Not applicable

The absence of a merits opinion limits the value of the case as precedent. Its principal importance is commercial: it resolved one generic challenger’s threat to Aubagio and preserved confidentiality around the negotiated entry terms.

What Orange Book patents and method-of-use claims mattered?

Aubagio’s patent estate was primarily a method-of-use estate rather than a conventional composition-of-matter estate.

Method-of-use protection

The asserted claims focused on using teriflunomide to treat multiple sclerosis, including dosage and administration concepts. This type of patent protection can be narrower than a composition patent because the generic applicant may attempt to market the product with a “skinny label” that omits patented indications.

Section viii carve-outs

Under 21 U.S.C. § 355(j)(2)(A)(viii), an ANDA applicant may omit a patented method of use from its proposed labeling. The viability of that strategy depends on whether the remaining label, promotional activity, prescribing practices, and induced-infringement evidence support a finding that the generic product would still encourage use of the patented method.

For Aubagio, method-of-use patents created a potential carve-out issue. Sanofi’s enforcement position would depend on the precise patent claims, Cadila’s proposed label, the indications retained in that label, and evidence concerning foreseeable use.

Patent estate strength

The estate had moderate litigation strength but lacked the breadth of a blocking composition-of-matter patent. Its strengths were:

• FDA listing of method-of-use patents.
• Multiple patents covering teriflunomide treatment concepts.
• A product with established use in a chronic disease.
• The ability to impose a Hatch-Waxman litigation stay.

Its limitations were:

• Dependence on claim construction and proof of infringement.
• Potential exposure to Section viii labeling strategies.
• Vulnerability to validity attacks based on written description, enablement, obviousness, or claim scope.
• Limited ability to block all teriflunomide sales after the relevant patents expired.

How did Sanofi’s Aubagio patents compare with a composition patent?

A composition patent generally provides broader protection than a method-of-use patent. If a valid composition patent covers teriflunomide itself, a generic product containing the active ingredient would face a direct infringement barrier. A method-of-use patent may be avoided through a label carve-out or by limiting the approved indication.

Protection type	Effect on generic risk
Composition-of-matter patent	Broadest protection; usually blocks the active ingredient
Formulation patent	Protects excipients, release profile, stability, or dosage form
Method-of-use patent	Protects a specified therapeutic use or dosing regimen
Manufacturing patent	May create process barriers but often does not block an alternative process
Regulatory exclusivity	Delays approval independently of patent validity

The Aubagio dispute was therefore more dependent on the scope of the asserted therapeutic-use claims than a case involving a single, broad compound patent.

Were formulation patents involved in this litigation?

The publicly identified Aubagio dispute centered on teriflunomide treatment patents. It was not principally a formulation-patent case involving a controlled-release system, injectable delivery device, or complex dosage technology.

Aubagio’s oral tablet formulation is comparatively conventional. The relevant competitive barriers were the active ingredient, approved indications, dosing claims, regulatory exclusivity, and method-of-use patents.

No public record from this action establishes a separate formulation settlement, manufacturing license, or technology-transfer agreement between Sanofi and Cadila.

Did the case involve a licensing deal or settlement agreement?

The case was resolved without publicly disclosed material settlement terms. The docket does not provide a complete public account of:

• Any authorized entry date.
• Any royalty rate.
• Whether Cadila received a license.
• Whether Sanofi agreed to supply product.
• Whether Cadila received authorized-generic rights.
• Whether the parties entered into a broader commercial collaboration.

Confidential settlements are common in Hatch-Waxman cases. The absence of published terms prevents a reliable determination of whether the resolution reflected an early-entry license, a no-launch covenant, a patent expiration agreement, or another commercial arrangement.

Under the FTC and Department of Justice framework, the commercial assessment of a pharmaceutical settlement would ordinarily consider whether the agreement included a payment from the brand company to the generic company, an agreed entry date, or restrictions beyond the patent’s lawful scope. No such terms should be inferred from the dismissal alone.

What generic launch risks existed for Aubagio?

The principal generic launch scenarios were as follows:

1. Cadila could prevail on invalidity or noninfringement and obtain approval after the statutory stay.
2. Cadila could enter under a settlement license before expiration of all asserted patents.
3. Cadila could use a Section viii carve-out for patented indications.
4. Cadila could launch after expiration of the remaining enforceable patents.
5. FDA approval could occur after litigation but commercial launch could be delayed by manufacturing, supply, or market-access considerations.

The risk to Sanofi increased as NCE exclusivity expired and additional ANDA applicants entered the market. Multiple generic approvals can rapidly compress price and volume, especially for an oral tablet product without a device-based switching barrier.

How did this case affect Sanofi’s commercial exposure?

Aubagio was a material specialty pharmaceutical product for Sanofi. Generic entry threatened:

• U.S. net sales.
• Prescription volume.
• Payer formulary position.
• Patient retention.
• International reference pricing.
• Sanofi’s ability to maintain price.

The commercial impact depended on the settlement entry date and the number of approved competitors. A single licensed entrant could produce a staged decline, while simultaneous entry by multiple manufacturers could cause rapid price erosion.

Because the Cadila settlement terms were confidential, the case record does not establish the precise revenue protection Sanofi obtained. The later loss of exclusivity for teriflunomide created a broader product-level exposure that could not be eliminated through one defendant-specific settlement.

Which companies challenged Aubagio patents?

Aubagio attracted ANDA activity from several generic manufacturers, including Cadila Healthcare and other major generic companies. The competitive field included companies commonly active in U.S. multiple-sclerosis and oral-solid-dose generic markets.

The existence of several challengers reduced the strategic value of settling with one defendant unless the settlement also provided a commercially favorable entry date or other enforceable restrictions. A settlement with Cadila did not remove the independent threat posed by other ANDA filers.

What is the precedent value of Sanofi v. Cadila?

The case has limited precedential value because it ended without a published merits decision. It does not establish a binding rule on:

• The construction of the asserted teriflunomide claims.
• The validity of the Aubagio patents.
• The sufficiency of a Paragraph IV notice.
• The legality of a Section viii carve-out.
• Induced infringement for teriflunomide.
• The enforceability of the settlement terms.

Its value is primarily transactional and competitive. It documents Sanofi’s enforcement strategy against an ANDA filer and confirms that Aubagio’s protection depended substantially on method-of-use patents and negotiated generic-entry risk.

Key Takeaways

• Sanofi-Aventis U.S. LLC v. Cadila Healthcare Ltd., 1:16-cv-01298, was an ANDA patent case involving generic teriflunomide, marketed by Sanofi as Aubagio.
• The dispute involved U.S. Patent Nos. 8,404,703 and 9,533,046, principally covering teriflunomide treatment methods.
• Aubagio’s five-year NCE exclusivity expired in September 2017.
• The case ended without a reported merits ruling on patent validity or infringement.
• Settlement terms, including any generic entry date or royalty arrangement, were not publicly disclosed.
• The case did not involve a biosimilar; it proceeded under the small-molecule ANDA pathway.
• The patent estate had meaningful Orange Book and litigation value but was narrower than a composition-of-matter estate.
• Generic launch risk increased as the principal patents approached expiration and additional ANDA applicants entered the market.
• The case provides limited judicial precedent but meaningful insight into Sanofi’s strategy for defending Aubagio against generic competition.

FAQs About Sanofi v. Cadila Healthcare

Was Sanofi v. Cadila a biologics or biosimilar case?

No. The case involved teriflunomide, a small-molecule active ingredient, and proceeded under the ANDA provisions of the Hatch-Waxman Act.

Did Cadila win the Aubagio patent litigation?

The public record does not show a merits victory for Cadila. The case was resolved and dismissed without a reported final ruling on infringement or patent validity.

What was the likely effect of the settlement on generic teriflunomide?

The settlement eliminated or postponed Cadila-specific litigation risk, but its precise effect cannot be determined because the material terms were not publicly disclosed.

Did Aubagio have a composition-of-matter patent blocking generics?

The litigation was principally associated with method-of-use patents. The public case record does not establish a surviving, broad composition-of-matter patent that independently blocked all teriflunomide products.

Is Sanofi v. Cadila useful for predicting other Hatch-Waxman cases?

It is useful for assessing settlement and lifecycle-management strategy, but it offers limited legal precedent because no published merits decision resolved the central patent issues.

References

1. U.S. District Court for the District of Delaware. (2016). Sanofi-Aventis U.S. LLC v. Cadila Healthcare Ltd., No. 1:16-cv-01298. PACER docket.

2. U.S. Food and Drug Administration. (2012). Aubagio (teriflunomide) prescribing information. FDA.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. United States Patent and Trademark Office. (2003). U.S. Patent No. 8,404,703: Teriflunomide for use in treating multiple sclerosis. USPTO.

5. United States Patent and Trademark Office. (2017). U.S. Patent No. 9,533,046: Teriflunomide treatment methods. USPTO.

6. Federal Trade Commission. (2013). Agreements filed with the Federal Trade Commission under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003. FTC.